The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Open accessAbstract
DNA repair competency is one determinant of sensitivity to certain chemotherapy drugs, such as cisplatin. Cancer cells with intact DNA repair can avoid the accumulation of genome damage during growth and also can repair platinum-induced DNA damage. We sought genomic signatures indicative of defective DNA repair in cell lines and tumors and correlated these signatures to platinum sensitivity. The number of subchromosomal regions with allelic imbalance extending to the telomere (NtAI) predicted cisplatin sensitivity in vitro and pathologic response to preoperative cisplatin treatment in patients with triple-negative breast cancer (TNBC). In serous ovarian cancer treated with platinum-based chemotherapy, higher levels of NtAI forecast a better initial response. We found an inverse relationship between BRCA1 expression and NtAI in sporadic TNBC and serous ovarian cancers without BRCA1 or BRCA2 mutation. Thus, accumulation of telomeric allelic imbalance is a marker of platinum sensitivity and suggests impaired DNA repair. Significance: Mutations in BRCA genes cause defects in DNA repair that predict sensitivity to DNA damaging agents, including platinum; however, some patients without BRCA mutations also benefit from these agents. NtAI, a genomic measure of unfaithfully repaired DNA, may identify cancer patients likely to benefit from treatments targeting defective DNA repair. Cancer Discov; 2(4); 366–75. ©2012 AACR. This article is highlighted in the In This Issue feature, p. 288
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Detection of large-scale variation in the human genome
Iafrate, A. J., Feuk, L., Rivera, M. N., Listewnik, M. L., Donahoe, P. K., Qi, Y., Scherer, S. W., & Lee, C. (2004) · Nature Genetics · doi:10.1038/ng1416 · Cited by 2,892
Large-scale copy number polymorphism in the human genome
Sebat, J., Lakshmi, B., Troge, J., Alexander, J., Young, J., Lundin, P., Månér, S., Massa, H., Walker, M., Chi, M., et al. (2004) · Science · doi:10.1126/science.1098918 · Cited by 2,557
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
Mechanisms of change in gene copy number
Hastings, P. J., Lupski, J. R., Rosenberg, S. M., & Ira, G. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2593 · Cited by 1,316
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P. A., Stratton, M. R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601894 · Cited by 1,267
Allele-specific copy number analysis of tumors
Van Loo, P., Nordgard, S. H., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V. J., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,226
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011 · cited 3×
“Reversion has also been seen in a cell line with a BRCA2 mutation selected for PARP inhibitor resistance (27).”
BackgroundBouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
Ogston, K. N., Miller, I. D., Payne, S., Hutcheon, A. W., Sarkar, T. K., Smith, I., Schofield, A., & Heys, S. D. (2003) · The Breast · doi:10.1016/s0960-9776(03)00106-1 · Cited by 982
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
Self-citationX chromosomal abnormalities in basal-like human breast cancer
Richardson, A. L., Wang, Z. C., De Nicolo, A., Lu, X., Brown, M., Miron, A., Liao, X., Iglehart, J. D., Livingston, D. M., & Ganesan, S. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.013 · Cited by 869
Self-citationXu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X.-W., Harris, C. C., Ried, T., & Deng, C.-X. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80466-9 · Cited by 819
Hastings, P. J., Ira, G., & Lupski, J. R. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000327 · Cited by 818
Lakhani, S. R., Reis-Filho, J. S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S., Bishop, T., Benitez, J., Rivas, C., Bignon, Y.-J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2424 · Cited by 611
BRCA1 dysfunction in sporadic basal-like breast cancer
Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., Savage, K., Gillett, C. E., Schmitt, F. C., Ashworth, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210014 · Cited by 573
Comparative Genomics and Molecular Dynamics of DNA Repeats in Eukaryotes
Richard, G.-F., Kerrest, A., & Dujon, B. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00011-08 · Cited by 546
Subtype and pathway specific responses to anticancer compounds in breast cancer
Heiser, L. M., Sadanandam, A., Kuo, W.-L., Benz, S. C., Goldstein, T. C., Ng, S., Gibb, W. J., Wang, N. J., Ziyad, S., Tong, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018854108 · Cited by 475
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457
ATR Homolog Mec1 Promotes Fork Progression, Thus Averting Breaks in Replication Slow Zones
Cha, R. S., & Kleckner, N. (2002) · Science · doi:10.1126/science.1071398 · Cited by 434
Improved survival in women with BRCA‐associated ovarian carcinoma
Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y. (2003) · Cancer · doi:10.1002/cncr.11310 · Cited by 433
Cancer predisposition caused by elevated mitotic recombination in Bloom mice
Luo, G., Santoro, I. M., McDaniel, L. D., Nishijima, I., Mills, M., Youssoufian, H., Vogel, H., Schultz, R. A., & Bradley, A. (2000) · Nature Genetics · doi:10.1038/82548 · Cited by 372
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
Tassone, P., Tagliaferri, P., Perricelli, A., Blotta, S., Quaresima, B., Martelli, M. L., Goel, A., Barbieri, V, Costanzo, F., Boland, C. R., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600859 · Cited by 361
Li, Y., Zou, L., Li, Q., Haibe-Kains, B., Tian, R., Li, Y., Desmedt, C., Sotiriou, C., Szallasi, Z., Iglehart, J. D., et al. (2010) · Nature Medicine · doi:10.1038/nm.2090 · Cited by 352
Self-citationResponse to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., Kladny, J., Gorski, B., Lubinski, J., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0128-9 · Cited by 340
Jetset: selecting the optimal microarray probe set to represent a gene
Li, Q., Birkbak, N. J., Gyorffy, B., Szallasi, Z., & Eklund, A. C. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-474 · Cited by 324
Self-citationYang, X. H., Sladek, T. L., Liu, X., Butler, B. R., Froelich, C. J., & Thor, A. D. (2001) · PubMed · Cited by 299
The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors
Kolomietz, E., Meyn, M. S., Pandita, A., & Squire, J. A. (2002) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10111 · Cited by 262
Drug transporters of platinum-based anticancer agents and their clinical significance
Burger, H., Loos, W. J., Eechoute, K., Verweij, J., Mathijssen, R. H. J., & Wiemer, E. A. C. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2010.12.002 · Cited by 230
Wang, Z. C., Lin, M., Wei, L.-J., Li, C., Miron, A., Lodeiro, G., Harris, L., Ramaswamy, S., Tanenbaum, D. M., Meyerson, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2570 · Cited by 190
Self-citationGenome Architecture Catalyzes Nonrecurrent Chromosomal Rearrangements
Stankiewicz, P., Shaw, C. J., Dapper, J. D., Wakui, K., Shaffer, L. G., Withers, M., Elizondo, L., Park, S.-S., & Lupski, J. R. (2003) · The American Journal of Human Genetics · doi:10.1086/374385 · Cited by 181
Schwartz, M., Zlotorynski, E., Goldberg, M., Ozeri, E., Rahat, A., le Sage, C., Chen, B. P. C., Chen, D. J., Agami, R., & Kerem, B. (2005) · Genes & Development · doi:10.1101/gad.340905 · Cited by 154
BRCA1 Is Required for Common-Fragile-Site Stability via Its G 2 /M Checkpoint Function
Arlt, M. F., Xu, B., Durkin, S. G., Casper, A. M., Kastan, M. B., & Glover, T. W. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6701-6709.2004 · Cited by 147
Bengtsson, H. L., Wirapati, P., & Speed, T. P. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp371 · Cited by 138
Further Evidence for BRCA1 Communication with the Inactive X Chromosome
Silver, D. P., Dimitrov, S. D., Feunteun, J., Gelman, R. S., Drapkin, R., Lu, S. D., Shestakova, E. A., Murugan, V., DeNunzio, N. J., Dragomir, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.02.025 · Cited by 83
Self-citationNeoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy
Ryan, P. D., Tung, N., Isakoff, S. J., Golshan, M. A., Richardson, A., Corben, A. D., Smith, B. L., Gelman, R. S., Winer, E. P., & Garber, J. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.551 · Cited by 82
Self-citationWhat drives recombination hotspots to repeat DNA in humans?
McVean, G. (2010) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2009.0299 · Cited by 72
Analysis of molecular inversion probe performance for allele copy number determination
Wang, Y.-K., Moorhead, M., Karlin-Neumann, G. A., Wang, N. J., Ireland, J. S., Lin, S., Chen, C., Heiser, L. M., Chin, K., Esserman, L. J., et al. (2007) · Genome biology · doi:10.1186/gb-2007-8-11-r246 · Cited by 67
Bengtsson, H. L., Neuvial, P., & Speed, T. P. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-245 · Cited by 63
Samouëlian, V., Maugard, C. M., Jolicoeur, M., Bertrand, R., Arcand, S. L., Tonin, P. N., Provencher, D. M., & Mes‐Masson, A. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0843-9 · Cited by 49
Fanconi Anemia: Causes and Consequences of Genetic Instability
Kalb, R., Neveling, K., Nanda, I., Schindler, D., & Hoehn, H. (2006) · KARGER eBooks · doi:10.1159/000092510 · Cited by 40
Mitotic maneuvers in the light
Vrieling, H. (2001) · Nature Genetics · doi:10.1038/88794 · Cited by 14
Cited by
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218
Self-citationBreast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136
Self-citation
Metadata
- Authors
- Birkbak, N. J., Wang, Z. C., Kim, J.-Y., Eklund, A. C., Li, Q., Tian, R., Bowman-Colin, C., Li, Y., Greene-Colozzi, A., Iglehart, J. D., Tung, N., Ryan, P. D., Garber, J. E., Silver, D. P., Szallasi, Z., & Richardson, A. L.
- Venue
- Cancer Discovery
- Published
- 2012-04-01
- Volume
- 2
- Issue
- 4
- Pages
- 366-375
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2168409298
- Cited by
- 661
- References
- 44
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.